983 related articles for article (PubMed ID: 11390488)
21. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
22. Adaptive immunity and enhanced CD8+ T cell response to Listeria monocytogenes in the absence of perforin and IFN-gamma.
Badovinac VP; Harty JT
J Immunol; 2000 Jun; 164(12):6444-52. PubMed ID: 10843700
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.
Yu Y; Cho HI; Wang D; Kaosaard K; Anasetti C; Celis E; Yu XZ
J Immunol; 2013 Feb; 190(4):1873-81. PubMed ID: 23315072
[TBL] [Abstract][Full Text] [Related]
24. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic effects of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 1999 Jun; 162(11):6671-80. PubMed ID: 10352285
[TBL] [Abstract][Full Text] [Related]
26. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
27. Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma.
Lipshy KA; Kostuchenko PJ; Hamad GG; Bland CE; Barrett SK; Bear HD
Ann Surg Oncol; 1997 Jun; 4(4):334-41. PubMed ID: 9181234
[TBL] [Abstract][Full Text] [Related]
28. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
Hu HM; Urba WJ; Fox BA
J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
30. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.
de Melo FM; Braga CJ; Pereira FV; Maricato JT; Origassa CS; Souza MF; Melo AC; Silva P; Tomaz SL; Gimenes KP; Scutti JA; Juliano MA; Zamboni DS; Câmara NO; Travassos LR; Ferreira LC; Rodrigues EG
Immunol Cell Biol; 2015 Jan; 93(1):86-98. PubMed ID: 25223833
[TBL] [Abstract][Full Text] [Related]
31. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
32. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
Roth E; Pircher H
J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
[TBL] [Abstract][Full Text] [Related]
33. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
34. Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.
Zilocchi C; Stoppacciaro A; Chiodoni C; Parenza M; Terrazzini N; Colombo MP
J Exp Med; 1998 Jul; 188(1):133-43. PubMed ID: 9653090
[TBL] [Abstract][Full Text] [Related]
35. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
[TBL] [Abstract][Full Text] [Related]
37. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
38. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines.
Winter H; van den Engel NK; Rüttinger D; Schmidt J; Schiller M; Poehlein CH; Löhe F; Fox BA; Jauch KW; Hatz RA; Hu HM
J Transl Med; 2007 Nov; 5():56. PubMed ID: 18001476
[TBL] [Abstract][Full Text] [Related]
40. Perforin-mediated effector function within the central nervous system requires IFN-gamma-mediated MHC up-regulation.
Bergmann CC; Parra B; Hinton DR; Chandran R; Morrison M; Stohlman SA
J Immunol; 2003 Mar; 170(6):3204-13. PubMed ID: 12626579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
